DATA GRAPHICS | Data Byte
Epkinly sales take off in its second quarter on the market
By Gunjan Ohri, Data Content Analyst
November 16, 2023 1:26 AM UTC
In its second quarter on the market, sales of Genmab and AbbVie’s subcutaneous CD20xCD3 bispecific, Epkinly, grew nearly fourfold, surpassing sales of competing intravenous CD20xCD3 bispecifics from Roche and Biogen.
FDA approved Epkinly epcoritamab, developed by partners Genmab A/S (CSE:GMAB; NASDAQ:GMAB) and AbbVie Inc. (NYSE:ABBV), on May 19 to treat diffuse large B-cell lymphoma (DLBCL) after two or more lines of treatment. The approval was the first of two this year for a CD20xCD3 bispecific in the indication, followed by Columvi glofitamab from Roche (SIX:ROG; OTCQX:RHHBY) on June 15…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/650674/comparing-sales-of-cd20xcd3-bispecifics-for-lymphoma